Vaxart, Inc. (NASDAQ:VXRT - Get Free Report)'s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.73 and traded as low as $0.72. Vaxart shares last traded at $0.74, with a volume of 1,361,347 shares traded.
Vaxart Stock Down 0.0 %
The business has a 50-day moving average price of $0.66 and a 200-day moving average price of $0.73. The firm has a market capitalization of $168.68 million, a P/E ratio of -1.81 and a beta of 0.62.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mesirow Financial Investment Management Inc. raised its holdings in shares of Vaxart by 100.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company's stock worth $34,000 after buying an additional 20,000 shares in the last quarter. XTX Topco Ltd raised its stake in Vaxart by 869.3% during the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock worth $116,000 after acquiring an additional 122,387 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Vaxart by 15.8% during the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company's stock valued at $2,160,000 after acquiring an additional 346,725 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Vaxart by 110.8% in the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company's stock valued at $2,660,000 after purchasing an additional 2,095,274 shares in the last quarter. Institutional investors own 18.05% of the company's stock.
About Vaxart
(
Get Free Report)
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
Featured Articles
Before you consider Vaxart, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.
While Vaxart currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
